ArticleMedical physics2021
Magnetic resonance biomarkers in radiation oncology: The report of AAPM Task Group 294.
Article in Medical physics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Weekly hippocampal diffusion changes during partial-brain radiation therapy for high-grade glioma: associations with dose and early memory change.Journal of neuro-oncology · 2026Observational
- Repeatability and reproducibility of MRI-derived radiomics on a 0.35 T MR-Linac using a tissue-mimicking phantom.Physics and imaging in radiation oncology · 2026Article
- Contrast-Enhanced MR Fingerprinting With Delta-Relaxometry: Investigating a New Avenue for Tumor Characterization.Journal of magnetic resonance imaging : JMRI · 2026Observational
- Apparent diffusion coefficient as a quantitative biomarker for prostate cancer treatment response on a 1.5 Tesla magnetic resonance-linear accelerator: Impact of image registration and acquisition type.Physics and imaging in radiation oncology · 2025Article
- Article
- Delta-Radiomics Using Machine Learning Classifiers With Auxiliary Data Sets to Predict Disease Progression During Magnetic Resonance-Guided Radiotherapy in Adrenal Metastases.JCO clinical cancer informatics · 2025Article
- The Use of Magnetic Resonance Imaging in Radiation Therapy Treatment Simulation and Planning.Journal of magnetic resonance imaging : JMRI · 2024Review
- Magnetic Resonance-Guided Cancer Therapy Radiomics and Machine Learning Models for Response Prediction.Tomography (Ann Arbor, Mich.) · 2024Review
- Imaging Assessment of Radiation Therapy-Related Normal Tissue Injury in Children: A PENTEC Visionary Statement.International journal of radiation oncology, biology, physics · 2024Review
- Predicting Radiotherapy Patient Outcomes with Real-Time Clinical Data Using Mathematical Modelling.Bulletin of mathematical biology · 2024Article
- Development and implementation of optimized endogenous contrast sequences for delineation in adaptive radiotherapy on a 1.5T MR-linear-accelerator: a prospective R-IDEAL stage 0-2a quantitative/qualitative evaluation ofJournal of medical imaging (Bellingham, Wash.) · 2023Article
- A Review on the Use of Imaging Biomarkers in Oncology Clinical Trials: Quality Assurance Strategies for Technical Validation.Tomography (Ann Arbor, Mich.) · 2023Review
- Functional information guided adaptive radiation therapy.Frontiers in oncology · 2023Article
- Review
- Tuning the optimal diffusion-weighted MRI parameters on a 0.35-T MR-Linac for clinical implementation: A phantom study.Frontiers in oncology · 2022Article
- Virtual Biopsy in Soft Tissue Sarcoma. How Close Are We?Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 13 institutions in 2 countries.
Funding
Abstract
purposeA magnetic resonance (MR) biologic marker (biomarker) is a measurable quantitative characteristic that is an indicator of normal biological and pathogenetic processes or a response to therapeutic intervention derived from the MR imaging process. There is significant potential for MR biomarkers to facilitate personalized approaches to cancer care through more precise disease targeting by quantifying normal versus pathologic tissue function as well as toxicity to both radiation and chemotherapy. Both of which have the potential to increase the therapeutic ratio and provide earlier, more accurate monitoring of treatment response. The ongoing integration of MR into routine clinical radiation therapy (RT) planning and the development of MR guided radiation therapy systems is providing new opportunities for MR biomarkers to personalize and improve clinical outcomes. Their appropriate use, however, must be based on knowledge of the physical origin of the biomarker signal, the relationship to the underlying biological processes, and their strengths and limitations. The purpose of this report is to provide an educational resource describing MR biomarkers, the techniques used to quantify them, their strengths and weakness within the context of their application to radiation oncology so as to ensure their appropriate use and application within this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.